Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat, Topotecan, and Pembrolizumab in Recurrent Small Cell Lung Cancer
NCT05353439Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2022
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tazemetostat in small cell lung cancer (SCLC), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 21 days and Incidence of Adverse Events at 3 years. Started Jul 2022; status: active, not recruiting.
02
Drugs
tazemetostat
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05353439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05353439.